These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22624634)

  • 41. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health technology assessment.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):105-11. PubMed ID: 10967621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Austria: history of health technology assessment during the past 20 years.
    Wild C
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():74-81. PubMed ID: 19500437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Guiding the process of health technology disinvestment.
    Ibargoyen-Roteta N; Gutiérrez-Ibarluzea I; Asua J
    Health Policy; 2010 Dec; 98(2-3):218-26. PubMed ID: 20638745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and test of a decision support tool for hospital health technology assessment.
    Sampietro-Colom L; Morilla-Bachs I; Gutierrez-Moreno S; Gallo P
    Int J Technol Assess Health Care; 2012 Oct; 28(4):460-5. PubMed ID: 23062518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Office of Technology Assessment health program.
    Banta D; Behney CJ
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():28-32. PubMed ID: 19519980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evidence-based framework for identifying technologies of no or low-added value (NLVT).
    Esandi ME; Gutiérrez-Ibarluzea I; Ibargoyen-Roteta N; Godman B
    Int J Technol Assess Health Care; 2020; 36(1):50-57. PubMed ID: 31831086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integration of health technology assessment recommendations into organizational and clinical practice: A case study in Catalonia.
    Gagnon MP; Sánchez E; Pons JM
    Int J Technol Assess Health Care; 2006; 22(2):169-76. PubMed ID: 16571192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of strengths, weaknesses, opportunities, and threats in the development of a health technology assessment program in Turkey.
    Kahveci R; Meads C
    Int J Technol Assess Health Care; 2008; 24(2):235-40. PubMed ID: 18400128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of programme budgeting and marginal analysis as a framework for resource reallocation in respiratory care in North Wales, UK.
    Charles JM; Brown G; Thomas K; Johnstone F; Vandenblink V; Pethers B; Jones A; Edwards RT
    J Public Health (Oxf); 2016 Sep; 38(3):e352-e361. PubMed ID: 26377991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA.
    Huic M; Tandara Hacek R; Svajger I
    Int J Technol Assess Health Care; 2017 Jan; 33(3):376-383. PubMed ID: 28803589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?
    ; Neumann PJ; Drummond MF; Jönsson B; Luce BR; Schwartz JS; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2010 Jan; 26(1):71-8. PubMed ID: 20059783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KNOW ESSENTIALS: a tool for informed decisions in the absence of formal HTA systems.
    Mathew JL
    Int J Technol Assess Health Care; 2011 Apr; 27(2):139-50. PubMed ID: 21447262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The uses of modern technologies: problems and perspectives for industrialized and developing countries.
    Banta D
    Bull Pan Am Health Organ; 1984; 18(2):139-50. PubMed ID: 6487871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.